down arrow

Imunon, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US15117N6022
USD
4.00
0.09 (2.3%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.904.08

52 Week

3.6041.22
Valuation
Technical
Day's Volume

CASH

58.57 k

Shareholding (Mar 2025)

FII

0.17%

Held by 6 FIIs

DII

97.96%

Held by 2 DIIs

Promoter

0.00%

How big is Imunon, Inc.?

22-Jun-2025

As of Jun 18, Imunon, Inc. has a market capitalization of 22.96 million, with net sales of 0.00 million and a net profit of -17.80 million. Shareholder's funds are 4.24 million and total assets are 9.72 million.

As of Jun 18, Imunon, Inc. has a market capitalization of 22.96 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters and a net profit of -17.80 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 4.24 million and total assets of 9.72 million.

Read More

What does Imunon, Inc. do?

22-Jun-2025

Imunon, Inc. is an oncology drug development company in the Pharmaceuticals & Biotechnology sector, with a market cap of USD 22.96 million and a recent net profit of -4 million. The company has no dividend yield and significant negative return on equity.

Overview:<BR>Imunon, Inc. is an oncology drug development company operating in the Pharmaceuticals & Biotechnology industry, with a market cap of USD 22.96 million.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 22.96 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.48 <BR>Return on Equity: -1,779.32% <BR>Price to Book: 22.96 <BR><BR>Contact Details:<BR>Address: 997 Lenox Dr Ste 100, LAWRENCE TOWNSHIP NJ: 08648-2317 <BR>Tel: 1 609 8969100 <BR>Fax: 1 609 8962200 <BR>Website: http://celsion.com/

Read More

Who are in the management team of Imunon, Inc.?

22-Jun-2025

As of March 2022, the management team of Imunon, Inc. includes Michael Tardugno as Executive Chairman, President, and CEO, along with independent directors Dr. Donald Braun, Dr. Pok Yu Chow, Frederick Fritz, Robert Hooper, and Mr. Andreas Voss.

As of March 2022, the management team of Imunon, Inc. includes Michael Tardugno, who serves as the Executive Chairman of the Board, President, and Chief Executive Officer. Additionally, the board consists of several independent directors: Dr. Donald Braun, Dr. Pok Yu Chow, Frederick Fritz, Robert Hooper, and Mr. Andreas Voss.

Read More

Is Imunon, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Imunon, Inc. has shifted to a bearish trend with weak strength indicators, supported by bearish signals from the MACD, Bollinger Bands, and daily moving averages, while showing some divergence in the OBV.

As of 10 September 2025, the technical trend for Imunon, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the weekly MACD and Bollinger Bands both signaling bearish conditions. The daily moving averages also confirm a bearish outlook. The Dow Theory reflects a mildly bearish sentiment on the weekly and monthly time frames, while the KST is bearish across both periods. The OBV shows a mildly bearish trend weekly but is bullish monthly, indicating some divergence. There is no multi-period return data available to compare the stock's performance against the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 15 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.48%

stock-summary
Debt Equity

-1.63

stock-summary
Return on Equity

-591.98%

stock-summary
Price to Book

5.52

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-30.19%
0%
-30.19%
6 Months
-83.94%
0%
-83.94%
1 Year
-64.09%
0%
-64.09%
2 Years
-67.56%
0%
-67.56%
3 Years
-79.14%
0%
-79.14%
4 Years
-96.99%
0%
-96.99%
5 Years
-96.56%
0%
-96.56%

Imunon, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Imunon, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Imunon, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the weekly MACD and Bollinger Bands both signaling bearish conditions. The daily moving averages also confirm a bearish outlook. The Dow Theory reflects a mildly bearish sentiment on the weekly and monthly time frames, while the KST is bearish across both periods. The OBV shows a mildly bearish trend weekly but is bullish monthly, indicating some divergence. There is no multi-period return data available to compare the stock's performance against the S&P 500....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-12.94%
EBIT Growth (5y)
3.46%
EBIT to Interest (avg)
-15.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.48
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
7.97%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
25.61
EV to EBIT
-1.27
EV to EBITDA
-1.32
EV to Capital Employed
-11.43
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1779.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.88%)

Foreign Institutions

Held by 6 Foreign Institutions (0.17%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 43.75% vs 14.29% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.60",
          "val2": "-4.80",
          "chgp": "45.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.70",
          "val2": "-4.80",
          "chgp": "43.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 4.62% vs 45.68% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.40",
          "val2": "-20.30",
          "chgp": "9.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.60",
          "val2": "-19.50",
          "chgp": "4.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.60
-4.80
45.83%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.70
-4.80
43.75%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 43.75% vs 14.29% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-18.40
-20.30
9.36%
Interest
0.00
0.20
-100.00%
Exceptional Items
0.00
-0.30
100.00%
Consolidate Net Profit
-18.60
-19.50
4.62%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 4.62% vs 45.68% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Imunon, Inc. stock-summary
stock-summary
Imunon, Inc.
Pharmaceuticals & Biotechnology
Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
Company Coordinates stock-summary
Company Details
997 Lenox Dr Ste 100 , LAWRENCE TOWNSHIP NJ : 08648-2317
stock-summary
Tel: 1 609 89691001 609 8969100
stock-summary
http://celsion.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."